Since 1874 遺伝子治療用製品の開発における 国内 …
製品（会社） ベクターの種類 導入遺伝子 適応症 開発段階 Glybera (UniQure ) AAV1 LPL S447Xvariant LPL欠損症 欧州承認2013 Imlygic (Amgen) 腫瘍溶解性HSV1 GM-CSF メラノーマ 欧米承認 2015 Strimvelis ）(GSK) レトロ（HSC ｱﾃﾞﾉｼﾝﾃﾞｱﾐﾅｰｾﾞ （ADA) ADA欠損症 欧州承認 2016 AAV2 -hRPE65v2
Download Since 1874 遺伝子治療用製品の開発における 国内 …
Information
Domain:
Source:
Link to this page:
Documents from same domain
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され， 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名： n-(2-
毒物及び劇物取締法Q＆A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q＆A 質問一覧 1．毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Risk Assessment and Management of Genotoxic ... …
www.nihs.go.jpRisk Assessment and Management of Genotoxic Impurities in Pharmaceuticals Masamitsu Honma, Ph.D. Division of Genetics and …
Related documents
Federated Kaufmann Fund
www.federatedinvestors.comSemi-Annual Shareholder Report April 30, 2018 Share Class | Ticker A | KAUAX B | KAUBX C |KAUCX R | KAUFX Institutional | KAUIX Federated Kaufmann Fund
Cellular Therapies – Program Chairs: Baculovirus ...
www.isbiotech.org2 ISBioTech 8th Spring Meeting (continued): TUESDAY MARCH 6, 2018• Viral Vectors & Vaccines Momentum, Third Floor Cellular Therapies Fusion, Third Floor
Corporate Overview - uniqure.com
www.uniqure.comThree Key Areas of Focus, each with proof-of-concept Hemophilia B uniQure is developing a gene therapy for hemophilia B, a severe orphan blood clotting disorder.
Since 1874 遺伝子治療とゲノム編集治療の 研究開 …
www.kantei.go.jpNIHS Since 1874. NIHS. Since 1874. 遺伝子治療とゲノム編集治療の. 研究開発の現状と課題. 国立医薬品食品衛生研究所. 遺伝子医薬部